SEC Form 4 · accession 0001193125-26-254589
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce N. Jacobs
Officer — Chief Financial Officer
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 7:30 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 2, 2026 | M | 12,653 | $2.08 | A | 260,241 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.08 | Jun 2, 2026 | M | 12,653 | D | — | Aug 28, 2029 | Common Stock | 12,653 | 0 | D |
Explanation of responses
- F1The shares underlying this stock option are fully vested and exercisable.